ZA977263B - Treatment of upper airway allergic responses. - Google Patents

Treatment of upper airway allergic responses.

Info

Publication number
ZA977263B
ZA977263B ZA9707263A ZA977263A ZA977263B ZA 977263 B ZA977263 B ZA 977263B ZA 9707263 A ZA9707263 A ZA 9707263A ZA 977263 A ZA977263 A ZA 977263A ZA 977263 B ZA977263 B ZA 977263B
Authority
ZA
South Africa
Prior art keywords
treatment
upper airway
allergic responses
airway allergic
responses
Prior art date
Application number
ZA9707263A
Other languages
English (en)
Inventor
William Kreutner
John A Hey
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA977263B publication Critical patent/ZA977263B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA9707263A 1996-08-16 1997-08-13 Treatment of upper airway allergic responses. ZA977263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68995196A 1996-08-16 1996-08-16

Publications (1)

Publication Number Publication Date
ZA977263B true ZA977263B (en) 1998-02-16

Family

ID=24770500

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707263A ZA977263B (en) 1996-08-16 1997-08-13 Treatment of upper airway allergic responses.

Country Status (25)

Country Link
EP (1) EP0920315B1 (pt)
JP (2) JP3638289B2 (pt)
KR (1) KR20000029975A (pt)
CN (1) CN1152682C (pt)
AR (1) AR008293A1 (pt)
AT (1) ATE314071T1 (pt)
AU (1) AU722040B2 (pt)
BR (1) BR9711149A (pt)
CA (1) CA2263163A1 (pt)
CO (1) CO4910138A1 (pt)
CZ (1) CZ43299A3 (pt)
DE (1) DE69734984D1 (pt)
HU (1) HUP9904362A3 (pt)
ID (1) ID17871A (pt)
IL (1) IL128573A0 (pt)
MY (1) MY116130A (pt)
NO (1) NO990706L (pt)
NZ (1) NZ334063A (pt)
PE (1) PE100298A1 (pt)
PL (1) PL191073B1 (pt)
SK (1) SK20099A3 (pt)
TR (1) TR199900326T2 (pt)
TW (2) TW200427450A (pt)
WO (1) WO1998006394A1 (pt)
ZA (1) ZA977263B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042379A2 (en) * 1997-03-26 1998-10-01 Sepracor Inc. Chemically and thermally stable norastemizole formulations
KR100514264B1 (ko) * 1997-08-26 2005-09-15 아벤티스 파마슈티칼스 인크. 피페리디노알칸올-충혈완화제 조합용 제약 조성물
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
ES2188029T3 (es) * 1997-11-07 2003-06-16 Schering Corp Fenil-alquil-imidazoles como antagonistas del receptor h3.
TW421645B (en) * 1997-11-07 2001-02-11 Schering Corp H3 receptor ligands of the phenyl-alkyl-imidazoles type
IL135727A0 (en) * 1997-11-07 2001-05-20 Schering Corp Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
JP2002527381A (ja) * 1998-10-09 2002-08-27 シェーリング コーポレイション アレルギー性疾患を処置するための組成物および方法
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
WO2001021162A2 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions using desloratadine
AU3800601A (en) 2000-02-03 2001-08-14 Schering Corporation Treating allergic and inflammatory conditions
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
AU2002244271A1 (en) 2001-03-13 2002-09-24 Pharmacopeia, Inc. Non-imidazole compounds as histamine h3 antagonists
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
PE20040464A1 (es) 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
MY135686A (en) 2002-06-24 2008-06-30 Schering Corp Indole derivatives useful as histamine h3 antagonists
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
WO2007001975A1 (en) 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
WO2010045306A2 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
EP2379565A1 (en) 2008-12-19 2011-10-26 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
PT2408453T (pt) 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
EP2429530B1 (en) * 2009-05-14 2018-11-07 The General Hospital Corporation (s)-meclizine for treating ischaemia-reperfusion injury
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
RU2685277C1 (ru) * 2018-05-24 2019-04-17 Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201683B (en) * 1987-08-04 1990-12-28 Biogal Gyogyszergyar Process for producing pharmaceutical compositions for promoting healing of wounds
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment

Also Published As

Publication number Publication date
JP2003095979A (ja) 2003-04-03
NO990706D0 (no) 1999-02-15
EP0920315B1 (en) 2005-12-28
AR008293A1 (es) 1999-12-29
PL331617A1 (en) 1999-08-02
CN1233179A (zh) 1999-10-27
CA2263163A1 (en) 1998-02-19
BR9711149A (pt) 1999-08-17
JP2000505094A (ja) 2000-04-25
WO1998006394A1 (en) 1998-02-19
DE69734984D1 (de) 2006-02-02
NO990706L (no) 1999-02-15
TW200427450A (en) 2004-12-16
PE100298A1 (es) 1999-01-11
TR199900326T2 (xx) 1999-05-21
AU3973397A (en) 1998-03-06
HUP9904362A2 (hu) 2000-11-28
AU722040B2 (en) 2000-07-20
CZ43299A3 (cs) 1999-07-14
KR20000029975A (ko) 2000-05-25
PL191073B1 (pl) 2006-03-31
JP3638289B2 (ja) 2005-04-13
CN1152682C (zh) 2004-06-09
ATE314071T1 (de) 2006-01-15
CO4910138A1 (es) 2000-04-24
NZ334063A (en) 2000-09-29
HUP9904362A3 (en) 2000-12-28
TWI221768B (en) 2004-10-11
EP0920315A1 (en) 1999-06-09
IL128573A0 (en) 2000-01-31
MY116130A (en) 2003-11-28
ID17871A (id) 1998-02-05
SK20099A3 (en) 2000-08-14

Similar Documents

Publication Publication Date Title
ZA977263B (en) Treatment of upper airway allergic responses.
AU7905894A (en) Treatment of poultry
IL128850A0 (en) Medical treatment
GB9411080D0 (en) Treatment
ZA966240B (en) Methods for treatment of allergic asthma.
AU2058697A (en) Treatment of sleep disorders
ZA979731B (en) Treatment of asthma.
AU3552697A (en) Novel treatment of leptine resistance
GB9410512D0 (en) Novel treatment
ZA971607B (en) Methods of treatment of allergic diseases
ZA973843B (en) Treatment of asthma with TNFR-lg.
GB9415901D0 (en) Novel compounds and treatment
GB9415900D0 (en) Novel compounds and treatment
GB9408084D0 (en) Medical treatment
IL119282A0 (en) Treatment of fowl
GB2324962B (en) Treatment of allergic conditions
GB9618290D0 (en) Treatment of diabetes
GB9709451D0 (en) Treatment of allergic conditions
IL127906A0 (en) Novel treatment of leptine resistance
GB9604008D0 (en) Treatment couch
GB9609897D0 (en) Treatment of diabetes
GB9604916D0 (en) Treatment of lead
HUP9902845A3 (en) Novel treatment of leptine resistance
GB9618375D0 (en) Medical treatment
GB9612330D0 (en) Medical treatment